$CRY (CryoLife Inc.)

$CRY {{ '2016-01-21T18:34:32+0000' | timeago}} • Announcement

Medical device company $CRY said it has acquired On-X Life Technologies Holdings, Inc. an Austin, Texas-based, mechanical heart valve maker.

$BIIB {{ '2017-09-25T14:11:23+0000' | timeago}} • Announcement

$BIIB appointed Camille Lee as Senior Vice President, Alzheimer’s Therapeutic Area, effective immediately. In this new role, she will report directly to Chief Medical Officer Alfred Sandrock, Jr., M.D., Ph.D. and will be based in Cambridge.

$BMY {{ '2017-09-25T13:27:21+0000' | timeago}} • Announcement

$BMY's Opdivo (nivolumab) receives FDA approval for intravenous use for the treatment of hepatocellular carcinoma patients previously treated with Sorafenib.

$LLY {{ '2017-09-25T13:18:33+0000' | timeago}} • Announcement

Geisinger and Boehringer Ingelheim, on behalf of its partnership with $LLY, announced that they will create a model to predict the three major outcomes associated with type 2 diabetes. The new model will allow to predict the complications from cardiovascular death, kidney failure and hospitalization for heart failure.

$AGN {{ '2017-09-25T12:27:39+0000' | timeago}} • Announcement

$AGN CFO Tessa Hilado has decided to retire from the company. Allergan has initiated a search to fill the position. Hilado will continue in her current role until a successor is named to ensure a smooth transition.

$AGN {{ '2017-09-25T12:23:08+0000' | timeago}} • Announcement

$AGN has authorized a new $2Bil share repurchase program, and has affirmed its commitment to increasing its regular quarterly cash dividend annually. The company also affirmed its 3Q17 revenue projection, which was issued on Aug 3, 2017.

$AGN {{ '2017-09-22T21:53:16+0000' | timeago}} • Announcement

$AGN received a Refusal to File letter from the US FDA on its Supplemental New Drug Application (sNDA) for Vraylar for treatment of negative symptoms associated with schizophrenia in adult patients. VRAYLAR is an oral antipsychotic approved in the US to treat schizophrenia. The FDA said the sNDA was not sufficient to permit a substantive review.

$AGN {{ '2017-09-22T14:30:34+0000' | timeago}} • Announcement

$AGN announced top-line results from new data for the Centaur Phase 2b study which supports the anti-fibrotic efficacy and safety of Cenicriviroc (CVC) for the treatment of liver fibrosis in adults with NASH. $AGN is currently enrolling patients in a 2,000 patient phase 3 clinical trial of CVC called the Aurora trial.

$ABT {{ '2017-09-22T12:26:48+0000' | timeago}} • Announcement

$ABT got the FDA nod for magnetic resonance (MR)-conditional labeling for its implantable cardioverter defibrillators (ICD) and associated high voltage leads. The new MR-conditional labeling for the Ellipse ICD allows patients to undergo an MRI scan. Patients implanted with Ellipse device and Durata or Optisure leads can also undergo MRI scans.

$ABBV {{ '2017-09-22T11:48:04+0000' | timeago}} • Announcement

$ABBV and $BMY announced a clinical trial collaboration to evaluate the combination of AbbVie's investigational antibody drug conjugate ABBV-399 and Bristol-Myers Squibb's immunotherapy Opdivo (nivolumab) in c-Met overexpressing non-small cell lung cancer (NSCLC).

$BMY {{ '2017-09-22T11:37:45+0000' | timeago}} • Announcement

$BMY announced that Japan Ministry of Health, Labor and Welfare approved 'Opdivo.' The nivolumab drug is used in the treatment of patients with unresectable advanced or recurrent gastric cancer progressing after chemotherapy.

$PFE {{ '2017-09-20T18:14:48+0000' | timeago}} • Announcement

$PFE filed a lawsuit against $JNJ over anticompetitive practices. The lawsuit alleges J&J violated federal antitrust laws by signing exclusionary contracts with health insurers, hospitals and doctor groups to ensure its medicine Remicade was given preferential treatment over Pfizer's new biosimilar Inflectra.

$BSX {{ '2017-09-19T15:14:32+0000' | timeago}} • Announcement

$BSX announced new data from the Multisensor Chronic Evaluation in Ambulatory Heart Failure Patients study evaluating the performance of the HeartLogic Heart Failure Diagnostic to predict impending heart failure decompensation. The data demonstrate alert improves heart failure risk prediction.

$BSX {{ '2017-09-18T14:02:45+0000' | timeago}} • Announcement

$BSX announced results from a 3-year follow-up cohort in its Post-FDA Approval Clinical Trial Evaluating Bronchial Thermoplasty in Severe Persistent Asthma (PAS2) study. The patients with severe asthma show sustained clinical improvement and the data confirmed long-term effectiveness of Bronchial Thermoplasty.

$MDT {{ '2017-09-18T13:29:52+0000' | timeago}} • Announcement

$MDT announced FDA approval and U.S. launch of the Intellis platform for the management of certain types of chronic intractable pain. The Intellis platform was designed to overcome limitations with current spinal cord stimulation (SCS) systems, such as battery performance, and can power the Evolve workflow.

$ABT {{ '2017-09-18T12:47:46+0000' | timeago}} • Announcement

$ABT is extending its previously announced tender offer to purchase all outstanding shares of Series B Convertible Perpetual Preferred Stock of Alere Inc. for $402 per share of Preferred Stock. The offer is being extended to allow additional time for the consummation of the merger, which is a condition to the completion of the offer.

$LIVN {{ '2017-09-14T20:47:42+0000' | timeago}} • Announcement

$LIVN intends to invest in inorganic opportunities within adjacent and underserved markets. The company expects to achieve revenue growth in the mid-single-digits in the near term and high-single-digits in the long term. $LIVN anticipates compounded annual earnings per share growth in the low- to mid-teens from 2017 to 2022.

$AMGN {{ '2017-09-14T19:26:48+0000' | timeago}} • Announcement

$AMGN and $AGN said the FDA has approved their Mvasi for the treatment of five types of cancer. Amgen and Allergan's bevacizumab biosimilar is also undergoing review by the European Medicines Agency, following a Marketing Authorization Application submitted in December 2016.

$AMGN {{ '2017-09-14T19:26:21+0000' | timeago}} • Announcement

$AMGN and $AGN said the FDA has approved their Mvasi (bevacizumab-awwb) for the treatment of five types of cancer. The approval was based on totality of evidence from global development program showing Mvasi is highly similar to Avastin. Mvasi is the first anti-cancer biosimilar, as well as first bevacizumab biosimilar, approved by the FDA.

$ABT {{ '2017-09-14T16:50:10+0000' | timeago}} • Announcement

$ABT BoD declared a quarterly common dividend of $0.265 per share. The dividend is payable Nov. 15, 2017, to shareholders of record at the close of business on Oct. 13, 2017.

$LLY {{ '2017-09-14T15:00:58+0000' | timeago}} • Announcement

$LLY and $INCY announced that new data from Phase 2 study of atopic dermatitis drug Baricitinib showed better outcomes. Atopic dermatitis is a type of inflammation of the skin, which results in itchy and red skin. Lilly and Incyte plans to start Phase 3 clinical program for atopic dermatitis later this year.

Recent Transcripts

MDT (Medtronic plc)
Tuesday, August 22 2017 - 12:00pm
LIVN (LivaNova PLC)
Wednesday, August 9 2017 - 1:00pm
NVAX (Novavax, Inc.)
Tuesday, August 8 2017 - 8:30pm
CMRX (Chimerix, Inc.)
Monday, August 7 2017 - 12:30pm
HAE (Haemonetics Corporation)
Monday, August 7 2017 - 12:00pm
AGN (Allergan plc)
Thursday, August 3 2017 - 12:30pm
TFX (Teleflex Incorporated)
Thursday, August 3 2017 - 12:00pm
GMED (Globus Medical, Inc.)
Wednesday, August 2 2017 - 9:30pm
TRXC (TransEnterix, Inc.)
Wednesday, August 2 2017 - 8:30pm
RMD (ResMed Inc.)
Tuesday, August 1 2017 - 8:30pm
PFE (Pfizer Inc.)
Tuesday, August 1 2017 - 2:00pm
ABBV (AbbVie Inc.)
Friday, July 28 2017 - 1:00pm
HRC (Hill-Rom Holdings, Inc.)
Friday, July 28 2017 - 12:30pm
SYK (Stryker Corporation)
Thursday, July 27 2017 - 8:30pm
BMY (Bristol-Myers Squibb Company)
Thursday, July 27 2017 - 2:30pm
KERX (Keryx Biopharmaceuticals Inc.)
Thursday, July 27 2017 - 12:00pm
BSX (Boston Scientific Corporation)
Thursday, July 27 2017 - 12:00pm
SNN (Smith & Nephew plc)
Thursday, July 27 2017 - 8:00am
MMSI (Merit Medical Systems, Inc.)
Wednesday, July 26 2017 - 9:00pm
IART (Integra LifeSciences Holdings Corporation)
Wednesday, July 26 2017 - 12:30pm

AlphaGraphics you may like